Abstract:Introduction Classification of mental disorders evolved greatly over time, as DSM and ICD dominated both research and everyday practice in the past decades. DSM-5 was planned to represent biological features of psychiatric disorders and include results of genetic and imaging studies in the criteria. Unfortunately, this goal couldn't be fulfilled, since, although there were promising results, evidence wasn't strong enough to fully support the biological background of the currently used diagnostic categories. One possible explanation for this discrepancy is that biological disturbances don't represent the somewhat artificial categorisation of these disorders. Many of the leading symptoms in psychotic disorders are nowadays considered as lying on a spectrum, such as autism, affective and psychotic spectrum disorders. Despite that, DSM-5 still describes schizophrenia, schizoaffective disorder and bipolar disorder as separate entities, however there can be major overlaps in the leading symptoms, moreover symptoms are not necessarily stable over time and can show fluctuations. It should be mentioned though that subgroups of schizophrenia in DSM-5 had been abolished and catatonia is considered as a trans-diagnostic specifier, moreover in ICD-11 certain symptoms can be added as symptoms specifiers to an existing diagnosis of primary psychotic disorder. Objectives Our aim was to establish a new trans-diagnostic, dimensional scale to assess the most important symptoms amongst patients with psychotic disorders. This scale is meant to represent the long-term clinical presentation and not a cross-sectional picture of a current state. We believe that long-term trajectories of these symptoms may be more connected to underlying biological features, such as genetic load (i.e. polygenic risk scores) and imaging results than the currently used diagnostic criteria. We think it is very important to create a tool, which is straightforward and short enough, so can be realistically used in everyday clinical work. This could provide important real-life data, which give us information about our patients from a different angle than the currently used diagnostic systems. Methods We have created the CPAN scale based on the current symptom specifiers of ICD-11 and the Clinician-Rated Dimensions of Psychosis Symptom Severity, which is an "emerging measure" for DSM-5 and also took into consideration our own clinical experience. Results The new tool measures 4 symptoms (catatonia, psychosis, affective symptoms and negative symptoms) on a scale of 5 (0-4). We have also put in specifiers to be able to characterize patients more precisely, and output measures (suicidal risk, functionality) to open the way for further analysis. Conclusions We tried to establish a novel symptom scale to help assessing patients with psychotic symptoms in everyday clinical work. Our plan is to test the validity of CPAN in the near future. Disclosure of Interest None Declared

SCAN: schedules fonr clinical assessment in neuropsychiatry

The Kiddie Schedule for Affective Disorders and Schizophrenia Present and Lifetime Version (K-SADS-PL) for DSM-5: A Validation for Neurodevelopmental Disorders in Japanese Outpatients

The Role of SCAN in Clinical Classification of Patients with Schizophrenia

Development and public release of a computerized adaptive (CAT) version of the Schizotypal Personality Questionnaire

Validation of the structured interview section of the penn computerized adaptive test for neurocognitive and clinical psychopathology assessment (CAT GOASSESS)

Psychosis Risk: Time to Look Empirically at a First-step Economical-pragmatic Way to Examine Anomalous Self-experience. Exploring the SQuEASE-11

CAMDEX: A Standardised Instrument for the Diagnosis of Mental Disorder in the Elderly with Special Reference to the Early Detection of Dementia

Empirically based assessment and taxonomy of psychopathology for ages 1½-90+ years: Developmental, multi-informant, and multicultural findings

Psychometric evaluation of the Symptom-Checklist-K-9 among U.S. working-age adults with psychiatric disabilities.

CPAN - A novel transdiagnostic dimensional approach to the assessment of psychotic disorders

Development of Screening Assessment for Capacity of Consent to Clinical Research and research on the reliability and validity of the tool in patients with schizophrenia

Screen for Cognitive Impairment in Psychiatry (SCIP): Adaptation and validation for Portuguese Version

The Seoul Neuropsychological Screening Battery (SNSB) for Comprehensive Neuropsychological Assessment

The Chinese-bilingual SCID-I/P Project: Stage 1 — Reliability for Mood Disorders and Schizophrenia

The Clinician's Subjective Experience during the Interaction with Adolescent Psychiatric Patients: Validity and Reliability of the Assessment of Clinician's Subjective Experience

The Application of K6 and SCL-8AD among Inpatients in A General Hospital

Social Cognition Psychometric Evaluation: Results of the Final Validation Study

Validity of Computer Based Administration of Cognitive Assessments compared to Traditional Paper-based Administration

Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care

Current Practice of Psychological Assessment.

Effects of Combining Pharmacotherapy with Cognitive Remediation